Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Konrad et al v. AbbVie, Inc. et al
Case Number:
1:15-cv-00966
Court:
Nature of Suit:
367(Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability)
Judge:
Firms
Companies
Sectors & Industries:
-
January 31, 2018
AbbVie Seeks New Trial After $140M AndroGel Verdict
AbbVie Inc. on Tuesday asked an Illinois federal judge for a new trial in the second bellwether case over claims the drugmaker failed to warn consumers about risks accompanying its testosterone treatment AndroGel, calling the $140 million verdict fatally inconsistent.
-
October 05, 2017
2nd Bellwether Jury Says AbbVie Owes AndroGel User $140M
An Illinois federal jury ordered AbbVie Inc. to pay an AndroGel user more than $140 million Thursday after finding the company failed to test its testosterone gel product properly for cardiovascular risks and misrepresented what it was safe to treat.
-
September 06, 2017
CORRECTION: AbbVie Can't Argue AndroGel Suit Too Late
An Illinois federal judge refused to reconsider an earlier ruling on whether an AndroGel user’s claims against AbbVie are barred by state statute of repose and statute of limitations Wednesday, shutting the door on some of the drugmaker’s defenses ahead of the next bellwether in the multidistrict litigation. Correction: An earlier version of this story misstated the ruling made by Judge Kennelly. The error has been corrected.
-
June 12, 2017
Mistrial Declared In First Androgel Bellwether
The first attempt to bring AbbVie Inc. to trial over the allegedly hidden side effects of its testosterone replacement drug Androgel ended in a mistrial Monday after the lead plaintiff's attorney fell ill.
-
June 06, 2017
Ex-FDA Head Says AbbVie Promoted Off-Label Androgel Use
Former U.S. Food and Drug Administration Commissioner David Kessler told jurors Tuesday that he felt AbbVie Inc. had stepped outside the bounds placed on it by the FDA by promoting testosterone replacement therapy drug Androgel for use in aging men without testing the safety of the drug.